iCAD - 10-Q quarterly report FY

 

(Mark One)

(603) 882-5200

Not Applicable

iCAD, INC.

INDEX

Balance Sheets
(unaudited)

Statements of Operations
(unaudited)

Statements of Cash Flows
(unaudited)

Reference should be made to iCAD, Inc.’s (“iCAD”, “Company”, “we”, “our” or “us”) Annual Report on Form 10-K for the year ended December 31, 2009 for a comprehensive summary of significant accounting policies.

The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”). In the opinion of management, these unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position at September 30, 2010, the results of operations for the three and nine month periods ended September 30, 2010 and 2009, and cash flows for the nine month periods ended September 30, 2010 and 2009. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with generally accepted accounting principles has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the SEC on March 23, 2010. The results for the three and nine month periods ended September 30, 2010 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2010, or any future period. Interim period amounts are not necessarily indicative of the results of operations for the full fiscal year.

In February 2010, the Financial Accounting Standards Board (“FASB”) issued ASU 2010-09,Subsequent Events (Topic 855) — Amendments to Certain Recognition and Disclosure Requirements (“ASU 2010-09”). ASU 2010-09 requires an entity that is an SEC filer to evaluate subsequent events through the date that the financial statements are issued and removes the requirement that an SEC filer disclose the date through which subsequent events have been evaluated. ASC 2010-09 was effective upon issuance. The adoption of this standard had no effect on our results of operation or our financial position.

The Company’s basic net (loss) income per share is computed by dividing net loss or income by the weighted average number of shares of common stock outstanding for the period and, if there are dilutive securities, diluted income per share is computed by including common stock equivalents which includes shares issuable upon the exercise of stock options, net of shares assumed to have been purchased with the proceeds, using the treasury stock method.

A summary of the Company’s calculation of net (loss) income per share is as follows:

The following table summarizes the number of shares of common stock for securities that were not included in the calculation of diluted net (loss) income per share because such shares are antidilutive:

The Company follows FASB Accounting Standards Codification (“ASC”) Topic 718, “Compensation - - Stock Compensation”, (“ASC 718”), for all share-based compensation that was not vested as of January 1, 2006. Under this application, the Company is required to record compensation expense for all awards granted after the date of adoption and for the unvested portion of previously granted awards that remain outstanding at the date of adoption.

The Company issued 530,500 shares of restricted stock and 186,018 stock options in the nine months ended September 30, 2010. The restricted stock granted during the first nine months of 2010 had a weighted average fair value of $1.41 per share. The options granted during the first nine months of 2010 had a weighted average exercise price of $1.65 per share. The weighted average fair value of options granted during this nine month period was $0.69 per share and was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted average assumptions: expected volatility of 69.17%, expected term of 3.5 years, risk-free interest rate of 2.14%, and expected dividend yield of 0%. The average expected life was calculated using the Company’s historical average life. The risk-free rate is based on the rate of U.S. Treasury zero-coupon issues with a remaining term equal to the expected life of option grants. The Company recorded $1,261,225 for share-based compensation for the nine months ended September 30, 2010.

For the same period in 2009, the Company issued 241,379 stock options. The Company did not issue any shares of restricted stock during this nine month period in 2009. The options granted during the first nine months of 2009 had a weighted average exercise price of $1.17 per share. The weighted average fair value of options granted during the nine month period ended September 30, 2009 was $0.43 per share and was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted average assumptions: expected volatility of 62.8%, expected term of 3.5 years, risk-free interest rate of 1.95%, and expected dividend yield of 0%. The Company recorded $1,494,894 for share-based compensation for the nine months ended September 30, 2009.

As of September 30, 2010, there was approximately $1,179,000 of total unrecognized compensation cost related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of three years.

The Company’s aggregate intrinsic value of options outstanding at September 30, 2010 was $488,616. The aggregate intrinsic value of restricted stock outstanding at September 30, 2010 was $1,400,424.

FASB ASC Topic 820, “Fair Value Measurement and Disclosures”, (“ASC 820”) defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

In accordance with ASC 820, the Company’s financial assets that are measured at fair value on a recurring basis as of September 30, 2010 are cash equivalents. The cash equivalents are measured using level one inputs.

In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (“CRA”) resulting from CRA’s audit of CADx Medical’s Canadian federal tax return for the year ended December 31, 2002. In February 2010, the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The CRA has the right to pursue the matter until July 2017. The Company believes that it is not liable for the re-assessment against CADx Medical and no accrual was recorded as of September 30, 2010.

At September 30, 2010, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740, “Income Taxes”. The Company does not expect that the unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any interest or penalties related to uncertain tax positions at September 30, 2010. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. On July 8, 2010, the Company was notified by the Internal Revenue Service of its intent to examine the tax returns for the 2008 tax year. Management cannot reasonably determine the results of this examination, if any, at this time. The Company is not under examination for any additional open tax years by the Internal Revenue Service or any other state and federal jurisdictions.

In accordance with FASB ASC Topic 350-20, “Intangibles — Goodwill and Other”, the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than its carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, changes in its results of operations and changes in its forecasts or market expectation relating to future results.

The Company’s goodwill arose in connection with its acquisitions in June 2002 and in December 2003. The Company operates in one segment and as one reporting unit since its products perform the same basic function, have common sales channels and/or resellers, and are developed and supported by one central staff. Therefore, the Company uses market capitalization as the best evidence of fair value (market capitalization is calculated using the quoted closing share price of the Company’s common stock at its annual impairment date of October 1, multiplied by the number of common shares outstanding) of the Company. The Company tests goodwill for impairment by comparing its market capitalization (fair value) to its carrying value. The fair value of the Company is compared to the carrying amount at the same date as the basis to determine if an impairment exists. The Company performed the step one fair value comparison as of October 1, 2010 and the Company’s market capitalization exceeded its carrying value.

Effective January 1, 2009, the Company adopted guidance now codified as FASB ASC Topic 805,“Business Combinations” (“ASC 805”). This topic requires an acquirer to recognize and measure the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree at their fair values as of the acquisition date. The topic requires acquisition costs and any restructuring costs associated with the business combination to be recognized separately from the fair value of the business combination. ASC 805 establishes requirements for recognizing and measuring goodwill acquired in the business combination or a gain from a bargain purchase as well as disclosure requirements designed to enable users to better interpret the results of the business combination. Early adoption of this topic was not permitted. The adoption of ASC 805 will impact the Company’s financial position, results of operations and cash flows to the extent it conducts acquisition-related activities and/or consummates business combinations. In the first nine months of 2010, the Company recorded expenses of approximately $1,140,000 primarily related to a potential acquisition that was not consummated and another that was under evaluation.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Certain information included in this Item 2 and elsewhere in this Form 10-Q that are not historical facts contain forward looking statements that involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare reimbursement policies, competitive factors, the effects of a decline in the economy in markets served by the Company and other risks detailed in the Company’s other filings with the SEC. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, “seek”, “should” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made.

iCAD is an industry-leading provider of advanced image analysis and workflow solutions that enable radiologists and other healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, expandable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT)). iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and colon cancer. Early detection of cancer is the key to better prognosis, less invasive and lower treatment costs, and higher survival rates. Performed as an adjunct to mammography screening, CAD has quickly become the standard of care in breast cancer detection, helping radiologists improve clinical outcomes while enhancing workflow. Computer-enhanced breast and prostate MRI analysis streamlines case interpretation workflow and generates more robust information for more effective patient treatment. CAD for mammography screening is also reimbursable in the U.S. under federal and most third-party insurance programs. Since receiving approval from the U.S. Food and Drug Administration (“FDA”) for the Company’s first breast cancer detection product in January 2002, over thirty nine hundred of iCAD’s CAD systems have been placed in mammography practices worldwide. iCAD is the only stand alone company offering CAD solutions for the early detection of breast cancer.

iCAD’s CAD mammography products have been shown to detect up to 72 percent of the cancers that biopsy proved were missed on the previous mammogram, an average of 15 months earlier. Our advanced pattern recognition technology analyzes images to identify patterns and then uses sophisticated mathematical analysis to mark suspicious areas.

The Company’s CAD systems include proprietary algorithm and other technology together with standard computer and display equipment. CAD systems for the film-based analog mammography market also include a radiographic film digitizer, either manufactured by the Company or others for the digitization of film-based medical images.

The Company intends to apply its core competencies in pattern recognition and algorithm development in disease detection to its future product development efforts. Its focus is on the development and marketing of cancer detection products for disease states where there are established or emerging protocols for screening as a standard of care. iCAD expects to pursue development or acquisition of products for select disease states that demonstrate one or more of the following: it is clinically proven that screening has a significant positive impact on patient outcomes, where there is an opportunity to lower health care costs, where screening is non-invasive or minimally invasive and where public awareness is high. The Company also intends to pursue opportunities beyond CAD through possible strategic acquisitions as part of its growth strategy, as such the Company continues to actively evaluate strategic opportunities in adjacent markets that could leverage its opportunities for growth beyond its historic core markets.

iCAD has applied its patented detection technology and algorithms to the development of CAD solutions for use with virtual colonoscopy or CT Colonography (CTC) to improve the detection of colonic polyps. The Company’s pattern recognition and image analysis expertise are readily applicable to colonic polyp detection and the Company has developed a CTC CAD solution. Virtual colonoscopy (CTC) is a technology that has evolved rapidly in recent years. Based on the results of the National CT Colonography trial, the Company expects that the market for virtual colonoscopy will grow along with the procedures for early detection of colon cancer. This trial demonstrated that CTC is highly accurate for the detection of intermediate and large polyps and that the accuracy of CTC is similar to a colonoscopy. CT Colonography or CTC is emerging as an alternative imaging procedure for evaluation of the colon. The Company has developed VeralookÔ, a product for computer aided detection of polyps in the colon using CTC and completed the clinical testing of its CTC CAD product in the first quarter of 2009. The Company filed a 510(k) application with the FDA in May 2009 seeking FDA clearance to market Veralook in the U.S and received FDA clearance on August 4, 2010. Colorectal cancer has been shown to be highly preventable with early detection and removal of polyps.

In July 2008, the Company acquired pharmaco-kinetic based CAD products that aid in the interpretation of contrast enhanced MRI images of the breast and prostate and began marketing these products in the fourth quarter of 2008. The interpretation of MRI exams also benefits from advanced image analysis and clinical decision support tools. MRI is an excellent tool to detect breast cancer as well as prostate cancer. While MRI is a more expensive option than traditional mammography, it enables physicians to view tumors which may have been missed during routine screenings. MRI uses magnets and radio waves instead of x-rays to produce very detailed, cross-sectional images of the body, and can be used to look specifically at those areas.

The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts and a research and development facility in Ohio.

The Company’s discussion and analysis of its financial condition, results of operations, and cash flows are based on the Company’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate these estimates, including those related to accounts receivable allowance, inventory valuation and obsolescence, intangible assets, income taxes, warranty obligations, contingencies and litigation. Additionally, the Company uses assumptions and estimates in calculations to determine stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The Company’s critical accounting policies are set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2009. The Company believes that revenue recognition is a critical accounting policy because it is governed by multiple complex accounting rules; however, there are no significant estimates or assumptions used in recording the Company’s revenue.

Revenue. Total revenue for the three and nine month periods ended September 30, 2010 was $5,586,357 and $18,204,165, respectively, compared with revenue of $7,106,270 and $20,001,155 for the three and nine month periods ended September 30, 2009, for a decrease of $1,519,913 and $1,796,990 or 21.4% and 9.0%, respectively. The decrease in revenue, for the three and nine month periods ended September 30, 2010, was due primarily to the decrease in digital and MRI CAD and film-based revenue partially offset by an increase in service and supply revenue.

The Company’s digital and MRI CAD revenue for the three and nine month periods ended September 30, 2010 decreased $1,497,449 and $1,217,366, or 31.1% and 9.6%, respectively, to $3,311,234 and $11,467,862, compared to sales of $4,808,683 and $12,685,228, respectively, in the same periods in 2009. The decrease in digital and MRI CAD revenue was largely the result of a combination of having a key OEM customer out of the market awaiting FDA approval of their new digital mammography system, and to the weakened economy as well as to continued budget constraints in healthcare capital spending.

Revenue from iCAD’s film based products for the three and nine month periods ended September 30, 2010 decreased 41.4% and 44.8%, respectively, to $748,093 and $2,519,551, compared to $1,275,884 and $4,561,053 in the three and nine month periods ended September 30, 2009. This decrease can be attributed to the softer demand for full field digital mammography systems which affects sales of TotalLook MammoAdvantage, current economic conditions and constraints in healthcare capital spending. The majority of film-based revenue is derived from sales of the Company’s TotalLook MammoAdvantage. The TotalLook MammoAdvantage product is used for digitizing film based prior mammography exams for comparative reading and is sold to further optimize workflow in a digital mammography environment. The TotalLook MammoAdvantage product is typically sold as customers are preparing to go digital. In addition, the demand for film-based products and accessories continues to decline as the marketplace continues to transition to digital technologies.

Service and supply revenue for the three and nine month periods ended September 30, 2010 increased 49.5% and 53.1%, respectively, to $1,527,030 and $4,216,752, compared to $1,021,703 and $2,754,874 in the same periods in 2009. The increase in the Company’s service and supply revenue is due primarily to increased service contract revenue on the Company’s growing installed base of products as customers migrate from warranty to service contracts, and to renewed service contract agreements. Service contract revenue as a percentage of the Company’s total service and supply revenue for the three and nine months ended September 30, 2010 represented 95% and 93%, respectively, compared to 91% and 92% for the same periods of 2009.

Gross Margin. Gross margin increased to 87.3% and 87.5% for the three and nine month periods ended September 30, 2010 compared to 84.8% and 83.0%, respectively, in the same three and nine month periods in 2009. The increase in total gross margin is primarily attributable to component cost reductions, the realization of some average selling price increases, and lower repair costs related to service contracts on a growing installed base of products.

Engineering and Product Development. Engineering and product development costs for the three month period ended September 30, 2010 increased slightly by $12,211, from $1,702,263 in 2009 to $1,714,474 in 2010. The increase in engineering and product development costs during this three month period was primarily due to the increase in subcontract services of $110,000, consulting services of $77,000 and licensing, data collection and travel expenses of $18,000 principally relating to new product development. These increases were partially offset by decreases in stock based and other compensation related expenses of $140,000 resulting primarily from staff reductions, as well as reductions in rent and legal expenses of $42,000, and various other expenses totaling $11,000.

Engineering and Product Development. Engineering and product development costs for the nine month period ended September 30, 2010 decreased by $805,810 or 14.4%, from $5,601,756 in 2009 to $4,795,946 in 2010. The decrease in engineering and product development costs during this nine month period was primarily due to decreases of $469,000 in stock based and other compensation related expenses resulting primarily from staff reductions, and in subcontracting services of $442,000 principally relating to the licensing and clinical trial costs for the Company’s CT Colon product which was completed in the first quarter of 2009. In addition, during the 2010 nine month period, the Company recorded decreases in legal costs of $97,000, in rent expense of $65,000 and in depreciation and various other expenses totaling $84,000. These decreases were partially offset by increases in consulting expenses of $173,000, subcontracting services of $159,000 and licensing and data collection expenses of $19,000, principally relating to new product development.

Marketing and Sales. Marketing and sales expense for the three and nine month periods ended September 30, 2010 increased by $189,327 or 7.3% and $466,641 or 5.7%, respectively, from $2,577,319 and $8,174,752 in 2009 to $2,766,646 and $8,641,393, respectively, in 2010. The increase in marketing and sales expense during the three and nine month periods of 2010 was primarily due to the increase in compensation related expenses for existing employees of $199,000 and $424,000, respectively, an increase in sales commissions of $51,000 and $91,000 and increases in consulting, advertising, education expenses and various marketing expenses totaling $16,000 and $174,000, respectively, principally relating to marketing consulting services incurred in the second quarter of 2010. These increases were partially offset by decreases in depreciation, freight and various administrative expenses totaling $77,000 and $222,000, respectively.

General and Administrative. General and administrative expenses for the three and nine month periods ended September 30, 2010 increased by $150,017 or 9.1%, and $924,776 or 17.8%, respectively, from $1,654,909 and $5,206,303 in 2009 to $1,804,926 and $6,131,079, respectively, in 2010. The increase in general and administrative expense during this three and nine month periods of 2010 was due primarily to an increase in legal and professional fees of $303,000 and $1,054,000 associated primarily with a potential acquisition that was not consummated and evaluation of another potential acquisition, increases in compensation related expenses of $71,000 and $296,000, and in provisions for taxes and various administrative expenses totaling $95,000 and $27,000, respectively. The increases in general and administrative expense during this three and nine month periods of 2010 were partially offset by a decrease in stock based compensation expense of $178,000 and $179,000, respectively, principally due to the completion of the three year vesting period on the awards of restricted stock and stock options that were granted to the executive officers of the Company in July 2007. In addition, during the three and nine month periods of 2010, the Company recorded decreases in legal, professional and consulting services totaling $108,000 and $209,000, respectively, and in insurance costs of $33,000 and $65,000, respectively.

Other Income: During the second quarter of 2010 the Company received a one-time payment of $275,000 related to the sale of a non-core patent that was acquired as part of the Qualia Computing, Inc. acquisition in 2003. The patent is for technology that is outside of the medical device industry and unrelated to the Company’s core business.

Interest Income/Expense. Net interest income for the three and nine month periods ended September 30, 2010 decreased by $4,345 and $30,524, respectively, from $22,965 and $88,641 in 2009 to $18,620 and $58,117 in the same periods of 2010. The decrease in interest income is due primarily to the reduction of the interest rate earned from the Company’s money market accounts.

Net Income/(Loss). As a result of the foregoing, the Company recorded a net loss of ($1,392,586) or ($0.03) per share for the three month period ended September 30, 2010 on revenue of $5,586,357, compared to net income of $112,758 or $0.00 per diluted share for the three month period ended September 30, 2009 on revenue of $7,106,270. The net loss for the nine months ended September 30, 2010 was ($3,313,312) or ($0.07) per share on revenue of $18,204,165, compared to a net loss of ($2,285,022) or ($0.05) per share on revenue of $20,001,155 for the nine months ended September 30, 2009.

Backlog. The Company’s product backlog (excluding service and supplies) as of September 30, 2010 totaled approximately $483,000 as compared to $663,000 at September 30, 2009 and $583,000 at June 30, 2010. It is expected that the majority of the backlog at September 30, 2010 will be shipped within the current fiscal year. Backlog as of any particular period should not be relied upon as indicative of the Company’s net revenues for any future period as a large amount of the Company’s product is booked and shipped within the same quarter.

The Company believes that its current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand and projected cash balances from continuing operations. The Company’s ability to generate cash adequate to meet its future capital requirements will depend primarily on operating cash flow. If sales or cash collections are reduced from current expectations, or if expenses and cash requirements are increased, the Company may require additional financing, although there are no guarantees that the Company will be able to obtain the financing if necessary. The Company will continue to closely monitor its liquidity and the capital and credit markets.

At September 30, 2010, the Company had current assets of $22,438,906, current liabilities of $7,726,902 and working capital of $14,712,004. The ratio of current assets to current liabilities was 2.9:1.

Net cash provided by operating activities for the nine months ended September 30, 2010 was $1,923,157, compared to net cash provided by operating activities of $559,202 for the same period in 2009. The cash provided by operating activities for the nine months ended September 30, 2010 resulted from decreases in accounts receivable of $1,574,216, inventory of $392,608, accrued expenses of $499,253 and deferred revenue of $876,703, plus non-cash items including depreciation and amortization totaling $1,241,976 and stock based compensation of $1,261,225, which were offset by the net loss of $3,313,312, the gain on the sale of a patent of $275,000, an increase in prepaid expenses, other current assets and deposits of $78,712 and a decrease in accounts payable of $255,800.

The net cash provided by investing activities for the nine months ended September 30, 2010 was $14,763, which consisted of proceeds from the sale of a patent of $275,000 offset by additions to patents, technology and other assets of $28,578 and additions to property and equipment of $231,659, compared to net cash used for investing activities for the nine months ended September 30, 2009 of $215,093, which consisted of additions to patents, technology and other assets of $88,549 and additions to property and equipment of $126,544.

Net cash used for financing activities for the nine months ended September 30, 2010 was $70,220 relating to taxes paid with respect to the issuance of restricted stock, compared to net cash provided by financing activities for the nine months ended September 30, 2009 of $23,494 due to cash received from the issuance of common stock relating to the exercise of stock options.

The following table summarizes, for the periods presented, the Company’s future estimated cash payments under existing contractual obligations at September 30, 2010.

Effective January 1, 2009, the Company adopted guidance now codified as FASB ASC Topic 805,“Business Combinations” (“ASC 805”). This topic requires an acquirer to recognize and measure the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree at their fair values as of the acquisition date. The topic requires acquisition costs and any restructuring costs associated with the business combination to be recognized separately from the fair value of the business combination. ASC 805 establishes requirements for recognizing and measuring goodwill acquired in the business combination or a gain from a bargain purchase as well as disclosure requirements designed to enable users to better interpret the results of the business combination. Early adoption of this topic was not permitted. The adoption of ASC 805 will impact the Company’s financial position, results of operations and cash flows to the extent it conducts acquisition-related activities and/or consummates business combinations. In the first nine months of 2010, the Company recorded expenses of approximately $1,140,000 primarily related to a potential acquisition that was not consummated and another that was under evaluation.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

The Company, under the supervision and with the participation of its management, including its principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934 (“Exchange Act”)) were effective at the reasonable level of assurance.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. The Company conducts periodic evaluations to enhance, where necessary its procedures and controls.

The Company’s principal executive officer and principal financial officer conducted an evaluation of the Company’s internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) to determine whether any changes in internal control over financial reporting occurred during the quarter ended September 30, 2010, that have materially affected or which are reasonably likely to materially affect internal control over financial reporting. Based on that evaluation, there has been no such change during such period.

The following table represents information with respect to purchases of common stock made by the Company during the three months ended September 30, 2010:

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.